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Abstract
Background: The objective of this study was to investigate the association between plasma 
concentrations of salicylic acid (SA) and other minor acetylsalicylic acid (ASA) metabolites 
and high on ASA platelet reactivity assessed with different methods in type 2 diabetic patients 
(T2DM). 
Methods: Study cohort consisted of 293 T2DM patients on chronic ASA therapy. Platelet 
function inhibition was analyzed using measurements of serum thromboxane B2 (S-TxB2), 
VerifyNow Aspirin and Platelet Function Analyzer (PFA)-100 assays. The concentration of ASA 
metabolites in plasma was measured with a high-performance liquid chromatography (HPLC).
Results: In logistic regression analysis both ASA dose/kg of body weight and plasma SA 
concentration were found to be predictive of S-TxB2 concentrations above 0.72 ng/mL cut-off 
point (OR 16.9, 95% CI 2.29–125.8, p = 0.006 and OR 5.34, 95% CI 2.67–10.68, p < 0.001, 
respectively). When using the VerifyNow Aspirin Assay, the concentrations of SA were signifi -
cantly lower (p = 0.007) in the group with high on ASA platelet reactivity when compared with 
the group with normal on ASA platelet reactivity. In logistic regression analysis plasma SA 
concentration was found to be predictive of VerifyNow Aspirin Reaction Units (ARU) ≥ 550 
(OR 3.86, 95% CI 1.86–8.00, p < 0.001). 
Conclusions: Our study suggests that disturbances of pharmacokinetic mechanisms might 
contribute to lower plasma SA levels, and subsequently incomplete inhibition of thromboxane A2 
synthesis as measured with S-TxB2 concentrations and increased platelet reactivity measured 
with VerifyNow in T2DM patients. (Cardiol J 2013; 20, 2: 170–177)
Key words: aspirin, diabetes, salicylic acid, platelet reactivity, platelet function 
testing
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Introduction
Acetylsalicylic acid (ASA) inhibits platelet 
aggregation through irreversible acetylation of 
platelet cyclooxygenase (COX)-1 and subsequent 
inhibition of the transformation of arachidonic acid 
(AA) into thromboxane A2 (TxA2), a potent vaso-
constrictor and aggregating agent [1]. ASA selec-
tively and rapidly acetylates the COX-1 enzyme, 
and is, in this respect, 166 fold more effective in 
inhibiting COX-1 than COX-2 enzyme. In addition, 
immediate ASA-degradation product, salicylic acid 
(SA), weakly binds to a COX-1 second binding site 
at Arg120 and may contribute to ASA antiplatelet 
effect [2]. Despite its well-documented therapeutic 
benefi ts, ASA treatment does not provide complete 
protection against cardiovascular events, which 
can be related to increased platelet reactivity. 
The reasons for such variability in the therapeutic 
response are poorly understood, though several 
studies have evaluated the effect of ASA to explain 
high platelet reactivity particularly in diabetic indi-
viduals on ASA therapy [3–7]. ASA is an effective 
inhibitor of platelet TxA2 production, nevertheless 
is often considered as overall relatively weak 
platelet inhibitor because of its limited effects on 
aggregation in the presence of high concentrations 
of such agonists as adenosine diphosphate (ADP) 
or collagen. This may account for some of the va-
riability of the response to these stimulants, which 
activate platelets through both COX-dependent and 
COX-independent pathways [8–13]. In addition, 
increased hydrolysis of circulating ASA, which 
corresponds to faster elimination of the drug from 
the circulation by degradation into SA and acetate, 
may also cause an altered response to ASA [6, 14].
The goal of this study has been to evaluate, in 
exclusively type 2 diabetes mellitus (T2DM) po-
pulation treated with ASA, whether an association 
could be observed between plasma concentrations 
of SA and other minor ASA metabolites and high 
on ASA platelet reactivity assessed with different 
methods. For this purpose TxA2 metabolites were 
measured in serum in order to obtain a specifi c 
measure of ASA-induced COX-1 inhibition. We also 
assessed the VerifyNow Aspirin Assay, which de-
monstrates very high sensitivity to COX-1 depen-
dent ASA effects [8]. In addition, shear dependent 
platelet functions were measured with less COX-1 
inhibition dependent device — Platelet Function 
Analyzer (PFA)-100. 
Methods
Patient population and study design
The local ethics committee of the Medical Uni-
versity of Warsaw approved both the study protocol 
and the informed consent form. The study was 
conducted in accordance with the current version 
of the Declaration of Helsinki at the time when the 
study was designed, and informed written consent 
was obtained from all patients. The study subjects 
were recruited consecutively from patients with 
T2DM participating in a multi-center, prospective, 
randomized, and open-label AVOCADO [Aspirin 
Vs/Or Clopidogrel in Aspirin-resistant Diabetics 
infl ammation Outcomes] study presenting to the 
outpatient clinic of the Central Teaching Hospital 
of the Medical University of Warsaw. The full 
characterization of the study population, including 
the inclusion and exclusion criteria were published 
previously [15]. Briefl y, 304 subjects with T2DM 
were recruited who, at the time of enrollment, had 
been taking ASA tablets at the dose of 75 mg per 
day for at least 3 months for primary or seconda-
ry prevention of myocardial infarction (MI). No 
clopidogrel or antiplatelet drugs other than ASA 
were used in any of the investigated patients. All 
patients had been taking oral antidiabetic agents 
and/or insulin for at least 6 months; diet-controlled 
diabetic patients were not included. Compliance to 
ASA therapy was determined at the study entry 
based upon the patient’s own statement and serum 
thromboxane B2 (S-TxB2) level measurement. 
Blood sample and assay procedures
Blood samples were collected in the morning, 
after an overnight fast and 2–3 hours after the last 
ASA dose. Blood was obtained from the antecubital 
vein, and the initial 2 mL of blood were discarded 
to avoid spontaneous platelet activation. Blood was 
drawn into tubes containing 3.2% sodium citrate for 
VerifyNow measurements, 3.8% sodium citrate for 
PFA-100 measurements. All blood samples were 
processed within 2 h of collection. Whole blood for 
S-TxB2 was allowed to clot at 37oC for 1 h before 
separating serum by centrifugation. Serum was 
obtained from venous blood by centrifugation at 
1000 g for 15 min at 4oC, and aliquots were stored 
at -80°C for further analysis. 
High-performance liquid chromatograp-
hy method for determination of ASA and its 
metabolites in plasma. The concentration of ASA 
172 www.cardiologyjournal.org
Cardiology Journal 2013, Vol. 20, No. 2
and its metabolites in plasma was measured by 
method described by Krivosikova et al. [16]. A high-
-performance liquid chromatograph (HPLC) system 
(Knauer, Germany) was equipped with UV variable 
wavelength diode array detector and C18 reverse 
phase column 150 × 3.9 mm (Waters). The mobile 
phase consisted of water-85% phosphoric acid-
-butanol-tetrabutylamoniumhydroxide-methanol 
(134:1:1:63). The fl ow rate was 0.9 mL/min, the sy-
stem was heated to 45oC, the wavelength of detector 
was set at 237 nm. Salicylic acid, gentisic acid (GA) 
(Sigma) and salicyluric acid (SUA) (all from Roth) 
were used as calibration standards. The chromato-
grams analysis was performed with ClarityChrom 
Software (Knauer, Germany) [16].
Serum thromboxane-B2 (S-TxB2). S-TxB2 
was measured also with an enzyme immunoassay kit 
according to the manufacturer’s instructions (Cay-
man Chemicals, Ann Arbor, MI, USA). Samples with 
results outside the standard curve were re-assayed 
with appropriate dilutions. An optimal compliance 
was confi rmed by S-TxB2 levels below 7.2 ng/mL 
in all patients as described previously in a diabetic 
population by Mortensen et al. [5].
Analysis of platelet functions. Platelet 
reactivity was measured with VerifyNow Aspirin 
Assay (Accumetrics, San Diego, CA, USA) and 
PFA-100 assay (Dade-Behring International, Inc., 
Newark, DE, USA). These assays were performed 
as described in detail previously [15]. In current 
study, normal platelet reactivity on ASA therapy 
with a PFA-100 was defi ned as collagen/epinephrine 
closure time (CEPI-CT) ≥ 193 s (the manufacturer’s 
lower limit of the normal range for aspirin-free he-
althy controls) and with VerifyNow Aspirin Assay as 
Aspirin Reaction Units (ARU) ≥ 550 [15].
Statistical analysis
Continuous variables are presented as mean ± 
± standard deviation and categorical variables 
are presented as frequencies and percentages. All 
variables were tested for non-normality by the Kol-
mogorov-Smirnov test. Continuous variables were 
compared using the Student T-test or the nonpara-
metric Mann-Whitney U test, and categorical variab-
les were compared using the χ2 or Fisher exact test, 
when applicable. Spearman’s Kendall and Pearson 
correlation coeffi cients were obtained to evaluate 
the association of ASA and metabolites levels and 
various phenotypic factors, including among others 
ASA dose in mg/kg of body weight, as well as resi-
dual platelet reactivity and S-TxB2 concentrations. 
A two-sided P-value of < 0.05 was considered 
significant. To determine parameters linked to 
ASA metabolism and residual platelet reactivity, 
recursive partitioning and logistic regression 
models were used to build binary classifi cation 
trees and to estimate odds ratios (OR) and 95% 
confi dence intervals (CI) for each splitting factor. 
We applied the Classifi cation Tree routine in the 
SPSS software to construct a classifi cation tree 
accounting for potential confounders. As an al-
ternative to logistic models, tree-based models 
rectify classifi cation analysis, and they are useful 
for non-linear dependent and for visualizing com-
plex interactions. Since recursive partitioning is 
exploratory and not hypothesis testing, multiple 
comparison tests were not applied. The end re-
sults of recursive partitioning were terminal nodes 
representing combinations of independent factors 
associated with an increased likelihood of high on 
ASA platelet reactivity. Analyses were performed 
with SPSS 20.0 for Windows (SPSS Institute, IL, 
USA). In all cases two-tailed p values < 0.05 were 
considered statistically signifi cant. 
Results
From the initially enrolled 304 patients, com-
plete clinical data and blood samples became ava-
ilable for 293 patients. Subsequently, 8 patients 
were eliminated from the analysis based on the 
suspected ASA non-compliance (S-TxB2 concen-
trations > 7.2 ng/mL). Demographic characteri-
stics, clinical data, and results of platelet function 
tests are summarized in Table 1. The variability 
of plasma concentrations of SA, GA and SUA in 
T2DM patients are illustrated in Figure 1. There 
was no statistically signifi cant correlation observed 
between independent binary variables (e.g., disease 
conditions or concomitant medications) and the plas-
ma concentrations of SA or other minor metabolites. 
No statistically signifi cant correlation was observed 
between plasma concentrations of SA, GA and SUA 
and continuous variables (Table 2).
The measured plasma concentrations of 
S-TxB2 varied widely between 0 and 6.9 ng/mL 
(median 0.153 ng/mL, interquartile range [IQR] 
0.05–0.61 ng/mL) in the investigated T2DM pa-
tients taking ASA for more than 3 months. No 
simple linear relationship was established between 
plasma concentrations of SA and S-TxB2 (data 
not shown). However, both bivariate correlation 
coeffi cients (Kendall’s tau b and Spearman’s rho 
between –0.23 and –0.33) showed low correlation 
for S-TxB2 with the plasma SA concentration at the 
p = 0.01 signifi cance level. In order to further 
analyze the relationship between S-TxB2 and SA 
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Table 1. Demographic and clinical characteristics of 
the study patients (n = 293).
Demographic
Age [years] 67.5 ± 8.7
Female gender 138 (47.1%)
Duration of diabetes [years] 10.2 ± 8.8
BMI [kg/m2] 31.19 ± 11.9
Dyslipidemia 240 (81.9%)
Hypertension 271 (92.5%)
CAD 164 (56.0%)
Prior MI 88 (30.0%)
Prior stroke 24 (8.2%)
Heart failure 109 (37.2%)
History of smoking 167 (57.0%)
Current smoking 29 (9.9%)
Concurrent medications
Oral hypoglycemic 252 (86.1%)
Insulin 93 (31.7%)
Beta-blockers 209 (71.3%)
ACE inhibitors 192 (65.5%)
Statins 210 (71.7%)
PPI 72 (24.9%)
Biochemical parameters
HGB [mmol/L] 8.6 ± 0.8
HCT 0.41 ± 0.04
RBC [1012/L] 4.6 ± 0.46
WBC [109/L] 7.1 ± 2.14
PLT [109/L] 226.1 ± 57.8
MPV [fl] 9.9 ± 1.2
eGFR [mL/min/1.73 m2] 71.0 ± 20.5
Creatinine [µmol/L] 88.4 ± 26.52
Fasting glucose [mmol/L] 7.5 ± 2.1
HbA1c [%] 7.0 ± 1.3
hsCRP [mg/L] 4.2 ± 5.8
Fibrinogen [µmol/L] 12.56 ± 3.1
Total cholesterol [mmol/L] 4.3 ± 1.0
Triglycerides [mmol/L] 1.52 ± 0.76
HDL-C [mmol/L] 1.26 ± 0.35
LDL-C [mmol/L] 2.29 ± 0.8
vWF% 136.7 (101.9–178.7)
S-TxB2 [ng/mL] 0.153 (0.049–0.61)
Verif yNow [ARU] 458 (417–518)
CEPI-CT [s] 265.00 (171.00–300.00)
CADP-CT [s] 97.00 (78.5–129.5)
Data are expressed as mean ± SD or N (%) or median (inter-
quartile range); BMI — body mass index; CAD — coronary 
artery disease; MI — myocardial infarction; ACE — angiotensin-
-converting enzyme; PPI — proton pump inhibitors; HGB — he-
moglobin; HCT — hematocrit; RBC — red blood cells; WBC — 
white blood cells; PLT — platelet count; MPV — mean platelet 
volume; eGFR — estimated glomerular filtration rate; HbA1c — 
glycosylated hemoglobin; hsCRP — high sensitivity C-reactive 
protein; HDL-C — high density lipoproteins cholesterol; LDL-C — 
low density lipoproteins cholesterol; vWF — von Willebrand 
factor; S-TxB2 — serum thromboxane-B2; ARU — aspirin rea-
ction units; CEPI-CT — collagen/epinephrine closure time by 
PFA-100 method; CADP-CT — collagen/adenosine diphosphate 
closure time by PFA-100 method
Figure 1. Frequency distribution of plasma concentra-
tions (in ng/µL) of salicylic acid (SA) (A), gentisic acid 
(GA) (B) and salicyluric acid (SUA) (C) in investigated 
diabetic population.
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(in binary format), we have established several 
empirical cut-off criteria (e.g., at 75th percentile — 
0.72 ng/mL, and at 95th percentile — 5.1 ng/mL) 
which divide the investigated patients into 
2 categories based on S-TxB2 concentration (0 = 
= response below selected cut-off point and 1 = 
= response above the selected cut-off point). Stati-
stically lower concentrations of SA were observed 
in the patients above both cut-off values (0.72 and 
5.1 ng/mL) of S-TxB2 concentrations (p < 0.0001 
and p = 0.003, respectively by Mann-Whitney test). 
The results of the hierarchical classifica-
tion tree analysis (recursive partitioning) of the 
independent factors involved in the different 
S-TxB2 concentrations (dependent variable) during 
prolonged ASA treatment is shown in Figure 2. 
S-TxB2 concentrations (at Node 0) were classi-
fi ed as 0 (below cut-off point) and 1 (above cut-
-off point) based on 75th percentile of observed 
S-TxB2 concentrations (0.72 ng/mL). The second 
level response (Node 1 and Node 2) were based 
on the calculated cut-off plasma concentration 
of SA (0.13 ng/µL), which created two different 
groups of patients with different effects on S-
-TxB2 concentrations (p < 0.001, χ2). The third 
level of response was only observed for Node 1 
(i.e. patients with SA plasma concentrations of 
< 0.13 ng/µL) and based on the ASA dose/kg of 
body weight (i.e. ≤ 0.862 mg/kg of body weight 
and > 0.862 mg/kg of body weight), and indicates 
that these two different groups of ASA/kg of body 
weight dosing displayed statistically signifi cant 
(p = 0.003, χ2) differences in effect of plasma 
SA concentration range which infl uence S-TxB2 
concentrations. In logistic regression analysis 
both ASA dose/kg of body weight and plasma SA 
concentration were found to be predictive of S-TxB2 
concentrations above cut-off point (i.e. 0.72 ng/mL) 
(OR 16.9, 95% CI 2.29–125.8, p = 0.006 and OR 
Figure 2. Hierarchical classification tree (recursive par-
titioning) analysis of the independent factors (salicylic 
acid [SA] plasma concentrations and acetylsalicylic acid 
[ASA] dose in mg/kg) involved in the different serum 
thromboxane-B2 (S-TxB2) response (dependent variable) 
during prolonged ASA treatment. S-TxB2 concentra-
tions (at Node 0) were classified as 0 (below cut-off 
point or normal on ASA platelet reactivity) and 1 (above 
cut-off point, or high on ASA platelet reactivity) based 
on 75th percentile of observed S-TxB2 concentrations 
(0.072 ng/mL). The second level (Node 1 and Node 
2) were based on the calculated cut-off plasma con-
centration of SA (0.13 ng/µL), which created two diffe-
rent groups of patients with different effects on S-TxB2 
(p < 0.001, c2). The third level was only observed for 
node 1 (i.e. patients with SA plasma concentrations of 
< 0.13 ng/µL) and based on the ASA dose/kg of body 
weight (i.e. ≤ 0.862 mg/kg and > 0.862 mg/kg), and 
indicates that these two different groups of ASA/kg of 
body weight dosing displayed statistically significant 
(p = 0.003, c2) differences in effect of SA concentration 
range which influence S-TxB2 concentration.
Table 2. Plasma concentrations in ng/µL of salicylic acid (SA), gentisic acid (GA) and salicyluric acid 
(SUA) in the population of diabetic patients during chronic acetylsalicylic acid (ASA) treatment.
SA [ng/µL] GA [ng/µL] SUA [ng/µL]
Mean 0.385120 4.9151 3.8675
Variance 0.436 14.237 13.225
Median 0.088763 3.9740 2.7315
Minimum 0.0000 0.47 0.13
Maximum      
Percentile      25th
3.1319
0.031106
17.25
2.2750
25.28
1.3113
                      50th 0.088763 3.9740 2.7315
                      75th 0.393150 6.7720 5.2190
sTXB2_cut 072
SA
Adj. P−value = 0.000, = 25.
0.58, df = 1
c2
ASA mg/kg
Adj. P−value = 0.003, = 14.
269, df = 1
c2
Node 0
Category % n
0.000
1.000
> 0.13425
Node 2
Category % n
£ 0.13425
Node 1
Category % n
£ 0.862
Node 3
Category % n
> 0.862: <missing>
Node 4
Category % n
0.000
1.000
Total
75.1
24.9
100.0
220
73
293
0.000
1.000
Total
64.8
35.2
60.1
114
62
176
106
11
117
90.6
9.4
39.9
0.000
1.000
Total
0.000
1.000
Total
49.4
50.6
26.3
38
39
77
76.8
23.2
33.8
76
23
99
0.000
1.000
Total
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5.34, 95% CI 2.67–10.68, p < 0.001, respecti-
vely). There was low linear correlation between 
SA concentration and VerifyNow ARU (Pearson 
–0.162, p = 0.003). The concentrations of SA were 
signifi cantly lower (p = 0.007) in the group with 
high on ASA platelet reactivity defi ned as ≥ 550 ARU 
(0.639 ng/mL) when compared with the group with 
normal on ASA platelet reactivity (0.101 ng/mL) 
(Fig. 3). In logistic regression analysis plasma SA con-
centration was found to be predictive of VerifyNow 
ARU ≥ 550 (OR 3.86, 95% CI 1.86–8.00, p < 0.001).
In respect to relation between CEPI-CT (as 
measured by PFA-100) and SA concentrations, 
statistically significant logarithmic regression 
was observed between SA concentrations split at 
0.13 ng/µL (Node 0 above, in hierarchical analysis) 
and CEPI-CT ≥ 193 s (OR 1.88, 95% CI 1.1–3.1, 
p < 0.015). No other analyzed independent va -
riables correlated with CEPI-CT threshold at 
³ 193 s (Fig. 4). Statistically signifi cant correlation 
(by Pearson, Kendall’s tau b and Spearman’s rho, 
p > 0.05) could be established between neither 
plasma concentrations of SA and CADP-CT original 
values (in [s]), nor between S-TxB2 and CADP-CT 
original values (in [s]) (data not shown). Moreover, 
no non-parametric correlation (Kendall’s tau and 
Spearman’s; p > 0.05) between HbA1c and CEPI-
Figure 4. Hierarchical classification tree (recursive parti-
tioning) analysis of the independent factors (i.e. plasma 
SA concentrations) involved in the collagen/epinephrine 
closure time (CEPI-CT) ≥ 193 s (dependent variable) 
during prolonged acetylsalicylic acid (ASA) treatment 
(see details in text). PFA-100 CEPI-CT (at Node 0) was 
classified as 0 (CEPI-CT ≥ 193 s) and 1 (CEPI-CT < 193 
s). The second level (Node 1 and Node 2) were based 
on the calculated cut-off plasma concentration of SA 
(0.13 ng/µL), which created two different groups of pa-
tients with different effects on CEPI-CT (p < 0.014, χ2).
-CT, CADP-CT, VerifyNow ARU, S-TxB2 and all 
measured ASA metabolites were found. In loga-
rithmic regression analysis only week correlation 
(p < 0.07) between HbA1c and CEPI-CT < 193 s, 
but not with CADP-CT, VerifyNow ARU and other 
measured parameters, was observed.
Discussion
The results of our study demonstrate that in 
the population of diabetic patients treated with ASA 
for primary or secondary prevention for the period 
of at least 3 months, plasma SA levels correlate 
with point-of-care platelet function assays used for 
determination of platelet reactivity, and can be to 
some degree predictive of S-TxB2 level, and thus 
platelet’s COX-1 inhibition. In the present study 
all investigated patients received the same dose of 
ASA, namely 75 mg daily, which is widely used in 
the clinical practice and, based on previous reports, 
appears suffi cient to fully inhibit COX-1 activity as 
demonstrated by > 95% inhibition of S-TxB2, at 
least in non-diabetic individuals [7, 17, 18]. 
Based on the cut-off values for S-TxB2 we 
excluded from further analysis 8 patients, and as 
the number of excluded patients was very low it 
does not appear to affect overall statistic calcula-
Figure 3. Plasma concentrations of salicylic acid (SA) in re-
lation to platelet activity evaluated using VerifyNow test. 
VerifyNow = 0 indicates normal on acetylsalicylic acid 
(ASA) platelet reactivity (Aspirin Reaction Units [ARU] 
< 550; N = 239 patients; 81.56%) and VerifyNow = 1 
indicates high on ASA platelet reactivity (ARU ≥ 550, 
N = 54 patients; 18.44%). Concentrations of SA was 
expressed in ng/µL. Statistical significance between 
groups was analyzed using Mann-Whitney test. Statisti-
cal significance was assumed at p < 0.05.
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tions. This approach is in agreement with current 
trend observed in lately published studies as lack 
of reliable method used for the assessment of 
compliance is consider to be a major limitation 
of previously published papers in this fi eld [5, 9].
ASA is mainly metabolized by the liver and in-
testinal human carboxylesterase-2 to acetyl and sa-
licylate moieties, and has a half-life of 15 to 20 min, 
whereas salicylate has a half-life of 3 to 6 h [19]. 
SA level measurements have been applied in order 
to assess compliance to ASA therapy according 
to numerous recently published studies [20–23]. 
However there are only few studies that directly 
evaluated the relationship between SA level and 
different tests of platelet function [22–24]. In our 
study S-TxB2 was < 7.2 ng/mL in vast majority of 
subjects, with exception of 8 patients, indicating 
low TxB2 generation, which confi rms the effective 
inhibitory effect of ASA on the COX-1 activity in 
platelets from blood samples collected in T2DM 
population treated with ASA for at least 3 months.
TxA2 is a potent platelet activator and vaso-
constrictor, and S-TxB2 is a measure of maximum 
platelet capacity to produce TxA2 [25]. Once-daily 
administration of low-dose ASA may be associa-
ted with incomplete inhibition of platelet COX-1 
activity and thromboxane-dependent function in 
diabetics [3, 4, 23, 26]. In the present study, despite 
the lack of simple linear relationship between plas-
ma concentrations of SA and the S-TxB2, we found 
lower concentrations of SA in several groups of 
patients selected based on empirical cut-off points 
for S-TxB2. In a further analysis predictive factors 
involved in the different S-TxB2 concentrations 
were low SA plasma concentrations. In contrary 
to our study Pulcinelli et al. [22] did not fi nd any 
correlation between plasma SA level and S-TxB2 
production. In addition, in a previously published 
HPLC in pharmacokinetic study aimed on 24-h 
variations of biological sensitivity to ASA and 
platelet reactivity measured with AA induced light 
transmission aggregometry (LTA) in population of 
patients with coronary artery disease (CAD) study 
by Henry at al. [23], no differences were found 
between SA concentrations and platelet reactivity. 
It was previously reported, that an increased 
body weight has been associated with a lower 
biochemical responsiveness to ASA, as assessed 
by S-TxB2 or platelet function assays, and with 
a possible lower clinical effi cacy of low-dose ASA, 
although the clinical impact of this phenomenon has 
never been formally tested in large trials [27–29]. 
This pharmacokinetic-based mechanism reducing 
ASA responsiveness in a fraction of patients with 
obesity may be especially important in T2DM. 
Based on these considerations, we calculated 
ASA dose in mg/kg of body weight, and we found 
that lower dose of ASA based on the ASA dose 
per kg of body weight can predict higher S-TxB2 
concentrations. As it was suggested by others, 
the higher doses or twice daily dosing of ASA 
may overcome the reduced platelet response to 
ASA, thus increased platelet reactivity, observed 
in diabetic patients [3, 26]. 
Moreover, based on our analysis we found the 
lower plasma concentration of SA in patients with 
high platelet reactivity based on VerifyNow mea-
surements. In addition, the subsequent analysis 
showed that low SA plasma concentrations have 
a predictive value for high on ASA platelet rea-
ctivity mesured with this COX-1 specifi c method. 
In our study, SA concentrations were also higher 
in patients with normal on ASA platelet reactivity 
measured with PFA-100 CEPI-CT assay when 
compared with patients with high on ASA platelet 
activity. No correlation could be established in our 
study between the history of CAD in the investi-
gated cohort of T2DM patients, platelet functions 
parameters or the plasma concentrations of ASA 
metabolites. Similarly to our results, in the small 
study of 10 MI survivors and 10 healthy controls, 
Ahmed et al. [24] did not fi nd any correlation be-
tween SA level and PFA-100 CEPI-CT in survivors 
of MI taking different doses of ASA ranging from 
75 to 300 mg per day. In another study, diabetic 
patients with CAD had signifi cantly higher levels of 
both platelet aggregation and activation compared 
to non-diabetic patients with CAD despite treat-
ment with the same dosage of ASA [5]. 
Limitations of the study
The inherent limitations of observational 
design apply to this study. It may be argued that 
we did not apply an LTA as a standard method for 
the platelet activation measurements. Instead we 
applied the measurement of the serum level of 
TxB2 as a good confi rmation of adequate complian-
ce to a daily ASA therapy, as well platelet COX-1 
dependent TxB2 synthesis inhibition. Pretreatment 
measurements could not be conducted because all 
patients included in this study had diagnosed CAD 
or multiple risk factors for CAD and therefore were 
on ASA therapy at the time of enrollment. Finally, 
it needs to be mentioned here that the results 
obtained must be interpreted with caution as lack 
of control group without diabetes do not allow 
to directly assess the impact of diabetes on ASA 
pharmacokinetics. 
177
Marek Postula et al., Salicylic acid and high on ASA platelet reactivity in diabetes
www.cardiologyjournal.org
Conclusions
In conclusion, our observational study found 
that disturbances of pharmacokinetic mechanisms 
associated with diabetes might contribute to lower 
SA levels in some patients, and thus incompletely 
inhibited TxA2 synthesis measured with S-TxB2 
concentrations and increased platelet reactivity 
measured with VerifyNow. Further pharmacoki-
netic and pharmacodynamic studies are needed to 
investigate the relationship between low platelet 
inhibition and ASA metabolites in diabetic patients, 
in particular with concomitant CAD. 
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